DYN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DYN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Dyne Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $4.85 Mil. Dyne Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $19.14 Mil. Dyne Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2024 was $-386.63 Mil. Dyne Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.06.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Dyne Therapeutics's Debt-to-EBITDA or its related term are showing as below:
During the past 7 years, the highest Debt-to-EBITDA Ratio of Dyne Therapeutics was -0.07. The lowest was -0.22. And the median was -0.15.
The historical data trend for Dyne Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyne Therapeutics Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | - | -0.22 | -0.18 | -0.11 | -0.07 |
Dyne Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.10 | -0.10 | -0.09 | -0.06 | -0.06 |
For the Biotechnology subindustry, Dyne Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dyne Therapeutics's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Dyne Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (4.85 | + | 19.138) | / | -342.213 | |
= | -0.07 |
Dyne Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (4.85 | + | 19.138) | / | -386.632 | |
= | -0.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.
Dyne Therapeutics (NAS:DYN) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Dyne Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard William Scalzo | officer: See Remarks | 25 ALBERTA LANE, HOLLISTON MA 01746 |
Oxana Beskrovnaya | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Dirk Kersten | director, 10 percent owner | C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC |
Carlo Incerti | director | FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC |
Jason P Rhodes | director, 10 percent owner | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Susanna Gatti High | officer: Chief Operating Officer | 75 LORIMER ROAD, BELMONT MA 02141 |
Wildon Farwell | officer: Chief Medical Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451 |
Jonathan Mcneill | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Joshua T Brumm | director, officer: See Remarks | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Atlas Venture Opportunity Fund I, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity Ii, Lp | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity Ii, Llc | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Romesh Subramanian | 10 percent owner, officer: Chief Scientific Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By Marketwired • 11-07-2024
By GuruFocus News • 02-03-2025
By GuruFocus News • 11-15-2024
By Marketwired • 02-03-2025
By GuruFocus News • 02-27-2025
By GuruFocus News • 11-14-2024
By Marketwired • 11-12-2024
By GuruFocus News • 02-14-2025
By Marketwired • 03-20-2025
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.